Shuichi Kanazashi
Director/Board Member chez SATSUMA PHARMACEUTICALS, INC.
Profil
Shuichi Kanazashi was the founder of UMN Pharma, Inc. (founded in 2004) and held the title of President & Chief Executive Officer from 2010 to 2012.
He is currently a Director at Satsuma Pharmaceuticals, Inc. (since 2023) and Chief Marketing Officer at Shin Nippon Biomedical Laboratories, Ltd.
(since 2002).
Dr. Kanazashi previously worked at Sony Group Corp.
and Nippon Roche KK as a Principal.
He obtained a doctorate degree from Kyoto University.
Postes actifs de Shuichi Kanazashi
| Sociétés | Poste | Début |
|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Sales & Marketing | 01/04/2020 |
| SATSUMA PHARMACEUTICALS, INC. | Director/Board Member | 08/06/2023 |
Anciens postes connus de Shuichi Kanazashi
| Sociétés | Poste | Fin |
|---|---|---|
| UMN PHARMA INC. | Founder | 01/03/2012 |
| SONY GROUP CORPORATION | Corporate Officer/Principal | - |
Nippon Roche KK
 Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The private company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Corporate Officer/Principal | - |
Formation de Shuichi Kanazashi
| Kyoto University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SONY GROUP CORPORATION | Electronic Technology |
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Entreprise privées | 3 |
|---|---|
Nippon Roche KK
Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The private company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Health Technology |
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
